Physician profile
Stephen M Day
NPI 1851397467
$1,667.39
in general payments reported to CMS, 2019-2025
20 companies · $268 in 2025
The $268 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $406 · 2020: $123 · 2021: $11.74 · 2022: $137 · 2023: $414 · 2024: $307 · 2025: $268.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $990.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $990.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $395.93 | 2019-2025 | |
| Amgen INC. | $277.75 | 2019-2025 | Repatha, Repatha |
| Abiomed | $119.27 | 2023-2025 | Impella |
| Sanofi-Aventis U.S. LLC | $109.94 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $95.32 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $87.46 | 2019-2025 | Camzyos |
| Amarin Pharma, INC. | $86.67 | 2019-2020 | |
| Pfizer INC. | $85.84 | 2023-2025 | |
| Cardiovascular Systems INC. | $82.75 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $59.97 | 2023-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $50.34 | 2020-2023 | Brilinta |
| Boston Scientific Corporation | $44.02 | 2019-2025 | Watchman Access System |
| Chiesi USA, INC. | $29.36 | 2024 | Kengreal |
| Celonova Biosciences, INC. | $28.43 | 2019-2020 | |
| Abbott Laboratories | $22.44 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vital Connect, INC | $21.48 | 2023 | Vitalpatch Rtm |
| Actelion Pharmaceuticals US, INC. | $20.19 | 2024 | Opsumit |
| Scpharmaceuticals INC. | $18.04 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.30 | 2025 | Jardiance |
| Shockwave Medical, INC | $14.89 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.